Sugi Predict

Sugi Predict / Compounds / SCHEMBL1298487

SCHEMBL1298487

SCHEMBL1298487

NC(=O)C(C[C@H](N)C(=O)O)C(N)=O

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 1/20 0.54
▸ SLC1A1 P43005 5/20 0.50
▸ SLC1A3 P43003 5/20 0.48
▸ SLC1A2 P43004 5/20 0.48
▸ ALOX15 P16050 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ PTGS1 P23219 1/20 0.46
▸ SLC7A11 Q9UPY5 1/20 0.46
▸ GRIK1 P39086 4/20 0.45
▸ GRIK2 Q13002 4/20 0.45
▸ GGT1 P19440 2/20 0.44
▸ GRM1 Q13255 1/20 0.44
▸ GRM2 Q14416 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27684600 0.95 SLC7A5 (0.54) SLC7A5SLC1A1SLC1A3SLC1A2ALOX15
SCHEMBL1843305 0.95 SLC7A5 (0.54) SLC7A5SLC1A1SLC1A3SLC1A2ALOX15
SCHEMBL445471 0.86 SLC7A5 (0.62) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
SCHEMBL39093 0.86 SLC7A5 (0.62) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
SCHEMBL148584 0.86 SLC7A5 (0.62) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
SCHEMBL4303994 0.86 SLC7A5 (0.62) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
SCHEMBL27287356 0.83 SLC1A1 (0.50) SLC7A5SLC1A1SLC1A3SLC1A2ALOX15
SCHEMBL27996271 0.83 SLC7A5 (0.54) SLC7A5SLC1A1SLC1A3SLC1A2GRIK1
SCHEMBL27996269 0.83 SLC7A5 (0.54) SLC7A5SLC1A1SLC1A3SLC1A2GRIK1
SCHEMBL27753461 0.81 SLC7A5 (0.42) SLC7A5SLC1A1SLC1A3SLC1A2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023247731-A1 ROR1/PTK7 BI-SPECIFIC ANTIGEN BINDING MOLECULES ALMAC DISCOVERY LIMITED (GB) 2023-12-28 — — WO disclosed
WO-2023247729-A1 ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES ALMAC DISCOVERY LIMITED (GB) 2023-12-28 — — WO disclosed
US-20230241072-A1 ANTHRACYCLINE DERIVATIVES ALMAC DISCOVERY LIMITED (GB) 2023-08-03 — — US disclosed
CN-103704735-A Processing method for goat blood tofu INST AGRO FOOD SCI & TECH CAAS 2014-04-09 — — CN disclosed
US-20130116302-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CHLAMYDIAL INFECTION MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2013-05-09 — — US disclosed
EP-2544671-A2 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CHLAMYDIAL INFECTION Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2013-01-16 — — EP disclosed
EP-1448593-B1 ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF ALBANY MEDICAL COLLEGE (US) 2012-01-11 — — EP disclosed
US-20110269692-A1 ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF ALBANY MEDICAL COLLEGE 2011-11-03 — — US disclosed
WO-2011110671-A2 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CHLAMYDIAL INFECTION MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-09-15 — — WO disclosed
US-7943577-B2 Alpha-fetoprotein peptides and uses thereof ALBANY MEDICAL COLLEGE (US) 2011-05-17 — — US disclosed
US-20090043073-A1 Alpha-fetoprotein peptides and uses for imaging ANDERSEN THOMAS T 2009-02-12 — — US disclosed
US-7220402-B1 Alpha-fetoprotein peptides and uses for imaging ORDWAY RESEARCH INSTITUTE, INC. (US) 2007-05-22 — — US disclosed
US-7122522-B2 Alpha-fetoprotein peptides and uses thereof CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. (US) 2006-10-17 — — US disclosed
US-20060199769-A1 ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-09-07 — — US disclosed
EP-1448593-A4 ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM INC (US) 2006-08-30 — — EP disclosed
WO-2003044040-A9 ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM INC (US) 2005-01-06 — — WO disclosed
EP-1448593-A2 ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF CLF Medical Technology Acceleration Program, Inc. (US) 2004-08-25 — — EP disclosed
WO-2003044040-A2 ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. (US) 2003-05-30 — — WO disclosed
WO-2003044041-A2 ALPHA-FETOPROTEIN PEPTIDES AND USES FOR IMAGING CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. (US) 2003-05-30 — — WO disclosed
CN-1239986-A Detergent compositions containing isopeptidase PROCTER & GAMBLE (US) 1999-12-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230241072-A1 ANTHRACYCLINE DERIVATIVES TOP2A, TOP2B, BCL6 SLC7A5 408/4885SLC1A1 2022/4885SLC1A3 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.